Literature DB >> 33092734

Proteomic Signatures of Heart Failure in Relation to Left Ventricular Ejection Fraction.

Luigi Adamo1, Jinsheng Yu2, Cibele Rocha-Resende3, Ali Javaheri4, Richard D Head2, Douglas L Mann5.   

Abstract

BACKGROUND: There is a growing recognition of the inherent limitations of the use of the left ventricular ejection fraction (LVEF) to accurately phenotype patients with heart failure (HF).
OBJECTIVES: The authors sought to identify unique proteomic signatures for patients with HF with reduced ejection fraction (HFrEF), HF with a midrange LVEF (HFmrEF), and HF with preserved ejection fraction (HFpEF), as well as to identify molecular differences between patients with ischemic and nonischemic HF.
METHODS: We used high-content aptamer-based proteomics technology (SOMAscan) to interrogate the blood proteome of age- and sex-matched patients with HF within different LVEF groups.
RESULTS: Within the Washington University Heart Failure Registry, we identified age/sex-matched patients within 3 LVEF categories: HFrEF (LVEF <40%), HFmrEF (LVEF 40% to 50%), and HFpEF (LVEF >50%). We found that patients with HFrEF, HFmrEF, and HFpEF had unique variations in circulating proteins that reflected distinct biological pathophysiologies. Bioinformatics analysis revealed that there were biological themes that were unique to patients with HFrEF, HFpEF, or HFmrEF. Comparative analyses of patients with HFmrEF with improved LVEF and patients with HFmrEF with unchanged LVEF revealed marked differences between these 2 patient populations and indicated that patients with recovered LVEF are more similar to patients with HFpEF than to patients with HFrEF. Moreover, there were marked differences in the proteomic signatures of patients with ischemic and nonischemic HF.
CONCLUSIONS: Viewed together, these findings suggest that it may be possible to use high-content multiplexed proteomics assays in combination with the clinical assessment of LVEF to more accurately identify clinical phenotypes of patients with HF. Published by Elsevier Inc.

Entities:  

Keywords:  heart failure; left ventricular ejection fraction; proteomics

Year:  2020        PMID: 33092734      PMCID: PMC7584807          DOI: 10.1016/j.jacc.2020.08.061

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  19 in total

Review 1.  Overflow of catecholamine neurotransmitters to the circulation: source, fate, and functions.

Authors:  M Esler; G Jennings; G Lambert; I Meredith; M Horne; G Eisenhofer
Journal:  Physiol Rev       Date:  1990-10       Impact factor: 37.312

2.  Biomarker Profiles of Acute Heart Failure Patients With a Mid-Range Ejection Fraction.

Authors:  Jasper Tromp; Mohsin A F Khan; Robert J Mentz; Christopher M O'Connor; Marco Metra; Howard C Dittrich; Piotr Ponikowski; John R Teerlink; Gad Cotter; Beth Davison; John G F Cleland; Michael M Givertz; Daniel M Bloomfield; Dirk J Van Veldhuisen; Hans L Hillege; Adriaan A Voors; Peter van der Meer
Journal:  JACC Heart Fail       Date:  2017-06-14       Impact factor: 12.035

3.  Accelerating Biomarker Discovery Through Electronic Health Records, Automated Biobanking, and Proteomics.

Authors:  Quinn S Wells; Deepak K Gupta; J Gustav Smith; Sean P Collins; Alan B Storrow; Jane Ferguson; Maya Landenhed Smith; Jill M Pulley; Sarah Collier; Xiaoming Wang; Dan M Roden; Robert E Gerszten; Thomas J Wang
Journal:  J Am Coll Cardiol       Date:  2019-05-07       Impact factor: 24.094

Review 4.  Structural and Functional Phenotyping of the Failing Heart: Is the Left Ventricular Ejection Fraction Obsolete?

Authors:  Michael R Bristow; David P Kao; Khadijah K Breathett; Natasha L Altman; John Gorcsan; Edward A Gill; Brian D Lowes; Edward M Gilbert; Robert A Quaife; Douglas L Mann
Journal:  JACC Heart Fail       Date:  2017-11       Impact factor: 12.035

Review 5.  Emerging Affinity-Based Proteomic Technologies for Large-Scale Plasma Profiling in Cardiovascular Disease.

Authors:  J Gustav Smith; Robert E Gerszten
Journal:  Circulation       Date:  2017-04-25       Impact factor: 29.690

6.  Heart Failure and Midrange Ejection Fraction: Implications of Recovered Ejection Fraction for Exercise Tolerance and Outcomes.

Authors:  Wilson Nadruz; Erin West; Mário Santos; Hicham Skali; John D Groarke; Daniel E Forman; Amil M Shah
Journal:  Circ Heart Fail       Date:  2016-04       Impact factor: 8.790

7.  Epidemiology, pathophysiology and clinical outcomes for heart failure patients with a mid-range ejection fraction.

Authors:  Ashish Rastogi; Eric Novak; Anne E Platts; Douglas L Mann
Journal:  Eur J Heart Fail       Date:  2017-06-14       Impact factor: 15.534

8.  Comparable performance of the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with preserved and reduced ejection fraction.

Authors:  Susan M Joseph; Eric Novak; Suzanne V Arnold; Philip G Jones; Himad Khattak; Anne E Platts; Victor G Dávila-Román; Douglas L Mann; John A Spertus
Journal:  Circ Heart Fail       Date:  2013-10-15       Impact factor: 8.790

9.  Reduced Apolipoprotein M and Adverse Outcomes Across the Spectrum of Human Heart Failure.

Authors:  Julio A Chirinos; Lei Zhao; Yi Jia; Cecilia Frej; Luigi Adamo; Douglas Mann; Swapnil V Shewale; John S Millar; Daniel J Rader; Benjamin French; Jeff Brandimarto; Kenneth B Margulies; John S Parks; Zhaoqing Wang; Dietmar A Seiffert; James Fang; Nancy Sweitzer; Christina Chistoffersen; Björn Dahlbäck; Bruce D Car; David A Gordon; Thomas P Cappola; Ali Javaheri
Journal:  Circulation       Date:  2020-04-02       Impact factor: 29.690

10.  Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial.

Authors:  Brian P Halliday; Rebecca Wassall; Amrit S Lota; Zohya Khalique; John Gregson; Simon Newsome; Robert Jackson; Tsveta Rahneva; Rick Wage; Gillian Smith; Lucia Venneri; Upasana Tayal; Dominique Auger; William Midwinter; Nicola Whiffin; Ronak Rajani; Jason N Dungu; Antonis Pantazis; Stuart A Cook; James S Ware; A John Baksi; Dudley J Pennell; Stuart D Rosen; Martin R Cowie; John G F Cleland; Sanjay K Prasad
Journal:  Lancet       Date:  2018-11-11       Impact factor: 79.321

View more
  17 in total

Review 1.  Heart failure with mildly reduced ejection fraction: from diagnosis to treatment. Gaps and dilemmas in current clinical practice.

Authors:  Marta Cvijic; Yelena Rib; Suzana Danojevic; Crina Ioana Radulescu; Natia Nazghaidze; Panos Vardas
Journal:  Heart Fail Rev       Date:  2022-07-25       Impact factor: 4.654

2.  Pediatric and adult dilated cardiomyopathy are distinguished by distinct biomarker profiles.

Authors:  Kory J Lavine; Kathleen E Simpson; Melanie R F Gropler; Steven E Lipshultz; James D Wilkinson; Jeffrey A Towbin; Steven D Colan; Charles E Canter
Journal:  Pediatr Res       Date:  2021-08-17       Impact factor: 3.953

Review 3.  Biomarkers in HFpEF for Diagnosis, Prognosis, and Biological Phenotyping.

Authors:  Moemen Eltelbany; Palak Shah; Christopher deFilippi
Journal:  Curr Heart Fail Rep       Date:  2022-10-05

4.  Proteomic Analysis of Effects of Spironolactone in Heart Failure With Preserved Ejection Fraction.

Authors:  Ali Javaheri; Ahmed Diab; Lei Zhao; Chenao Qian; Jordana B Cohen; Payman Zamani; Anupam Kumar; Zhaoqing Wang; Christina Ebert; Joseph Maranville; Erika Kvikstad; Michael Basso; Vanessa van Empel; A Mark Richards; Robert N Doughty; Ernst Rietzschel; Karl Kammerhoff; Joseph Gogain; Peter Schafer; Dietmar A Seiffert; David A Gordon; Francisco Ramirez-Valle; Douglas L Mann; Thomas P Cappola; Julio A Chirinos
Journal:  Circ Heart Fail       Date:  2022-08-09       Impact factor: 10.447

Review 5.  The Role of B Cells in Cardiomyopathy and Heart Failure.

Authors:  Kevin Bermea; Aashik Bhalodia; Angelo Huff; Sylvie Rousseau; Luigi Adamo
Journal:  Curr Cardiol Rep       Date:  2022-06-11       Impact factor: 3.955

6.  Glycocalyx Disruption Triggers Human Monocyte Activation in Acute Heart Failure Syndromes.

Authors:  Olga G Grushko; Steven Cho; Ashley M Tate; Robert S Rosenson; David J Pinsky; Jacob M Haus; Scott L Hummel; Sascha N Goonewardena
Journal:  Cardiovasc Drugs Ther       Date:  2022-10-19       Impact factor: 3.947

7.  Evaluating microbiome-directed fibre snacks in gnotobiotic mice and humans.

Authors:  Omar Delannoy-Bruno; Chandani Desai; Arjun S Raman; Robert Y Chen; Matthew C Hibberd; Jiye Cheng; Nathan Han; Juan J Castillo; Garret Couture; Carlito B Lebrilla; Ruteja A Barve; Vincent Lombard; Bernard Henrissat; Semen A Leyn; Dmitry A Rodionov; Andrei L Osterman; David K Hayashi; Alexandra Meynier; Sophie Vinoy; Kyleigh Kirbach; Tara Wilmot; Andrew C Heath; Samuel Klein; Michael J Barratt; Jeffrey I Gordon
Journal:  Nature       Date:  2021-06-23       Impact factor: 49.962

8.  Therapeutic Targets for Heart Failure Identified Using Proteomics and Mendelian Randomization.

Authors:  Anders Mälarstig; Aroon D Hingorani; R Thomas Lumbers; Albert Henry; María Gordillo-Marañón; Chris Finan; Amand F Schmidt; João Pedro Ferreira; Ravi Karra; Johan Sundström; Lars Lind; Johan Ärnlöv; Faiez Zannad
Journal:  Circulation       Date:  2022-03-18       Impact factor: 39.918

9.  Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection.

Authors:  Emma S Winkler; Pavlo Gilchuk; Jinsheng Yu; Adam L Bailey; Rita E Chen; Zhenlu Chong; Seth J Zost; Hyesun Jang; Ying Huang; James D Allen; James Brett Case; Rachel E Sutton; Robert H Carnahan; Tamarand L Darling; Adrianus C M Boon; Matthias Mack; Richard D Head; Ted M Ross; James E Crowe; Michael S Diamond
Journal:  Cell       Date:  2021-02-12       Impact factor: 66.850

10.  Clinical Phenotypes and Age-Related Differences in Presentation, Treatment, and Outcome of Heart Failure with Preserved Ejection Fraction: A Vietnamese Multicenter Research.

Authors:  Ngoc-Thanh-Van Nguyen; Diep Tuan Tran; Pham Le An; Sy Van Hoang; Hoai-An Nguyen; Hoa Ngoc Chau
Journal:  Cardiol Res Pract       Date:  2021-01-15       Impact factor: 1.866

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.